Regal Investment Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-422
Closed -$214K 565
2023
Q3
$214K Sell
422
-132
-24% -$70.3K 0.02% 456
2023
Q2
$289K Sell
554
-22
-4% -$11.9K 0.02% 400
2023
Q1
$332K Sell
576
-2,082
-78% -$1.17M 0.03% 363
2022
Q4
$1.46M Buy
2,658
+16
+0.6% +$8.48K 0.14% 149
2022
Q3
$1.34M Sell
2,642
-5
-0.2% -$2.8K 0.14% 147
2022
Q2
$1.44M Sell
2,647
-84
-3% -$46.2K 0.15% 141
2022
Q1
$1.61M Buy
2,731
+70
+3% +$40.2K 0.15% 142
2021
Q4
$1.77M Sell
2,661
-462
-15% -$288K 0.16% 139
2021
Q3
$1.78M Buy
3,123
+751
+32% +$412K 0.17% 135
2021
Q2
$1.2M Buy
+2,372
New +$1.12M 0.12% 184
2015
Q4
Sell
-320
Closed -$39K 814
2015
Q3
$39K Buy
320
+50
+19% +$6.51K 0.01% 458
2015
Q2
$35K Hold
270
0.01% 482
2015
Q1
$36K Buy
270
+200
+286% +$25.8K 0.01% 470
2014
Q4
$9K Hold
70
﹤0.01% 654
2014
Q3
$9K Hold
70
﹤0.01% 720
2014
Q2
$8K Hold
70
﹤0.01% 704
2014
Q1
$8K Buy
+70
New +$8.32K ﹤0.01% 678

Other funds holding TMO

Regal Investment Advisors's TMO Position: Q4 2023 in Review

Regal Investment Advisors sold out of Thermo Fisher Scientific (TMO) in Q4 2023, closing a stake of 422 shares — an estimated $214K sold.

Regal Investment Advisors first reported a position in TMO in Q1 2014 and held it in 17 quarters. The position peaked at $1.78M in Q3 2021. 2,487 funds tracked by Wall St. Rank hold TMO as of Q4 2023.

  • Regal Investment Advisors reported no remaining Thermo Fisher Scientific position as of Q4 2023 after selling out during the quarter.
  • Regal Investment Advisors sold 422 Thermo Fisher Scientific shares in Q4 2023, an estimated $214K.
  • Regal Investment Advisors first reported a position in Thermo Fisher Scientific in Q1 2014 and held it in 17 quarters.
  • Regal Investment Advisors's Thermo Fisher Scientific position peaked at $1.78M in Q3 2021.
  • 2,487 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2023.

Based on Regal Investment Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.